Passa al contenuto
Merck
  • A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression.

A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression.

The Journal of pathology (2014-10-29)
Brian W Simons, Nicholas M Durham, Tullia C Bruno, Joseph F Grosso, Anthony J Schaeffer, Ashley E Ross, Paula J Hurley, David M Berman, Charles G Drake, Praveen Thumbikat, Edward M Schaeffer
ABSTRACT

Inflammation is associated with several diseases of the prostate including benign enlargement and cancer, but a causal relationship has not been established. Our objective was to characterize the prostate inflammatory microenvironment after infection with a human prostate-derived bacterial strain and to determine the effect of inflammation on prostate cancer progression. To this end, we mimicked typical human prostate infection with retrograde urethral instillation of CP1, a human prostatic isolate of Escherichia coli. CP1 bacteria were tropic for the accessory sex glands and induced acute inflammation in the prostate and seminal vesicles, with chronic inflammation lasting at least 1 year. Compared to controls, infection induced both acute and chronic inflammation with epithelial hyperplasia, stromal hyperplasia, and inflammatory cell infiltrates. In areas of inflammation, epithelial proliferation and hyperplasia often persist, despite decreased expression of androgen receptor (AR). Inflammatory cells in the prostates of CP1-infected mice were characterized at 8 weeks post-infection by flow cytometry, which showed an increase in macrophages and lymphocytes, particularly Th17 cells. Inflammation was additionally assessed in the context of carcinogenesis. Multiplex cytokine profiles of inflamed prostates showed that distinct inflammatory cytokines were expressed during prostate inflammation and cancer, with a subset of cytokines synergistically increased during concurrent inflammation and cancer. Furthermore, CP1 infection in the Hi-Myc mouse model of prostate cancer accelerated the development of invasive prostate adenocarcinoma, with 70% more mice developing cancer by 4.5 months of age. This study provides direct evidence that prostate inflammation accelerates prostate cancer progression and gives insight into the microenvironment changes induced by inflammation that may accelerate tumour initiation or progression.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Acido cloridrico, ACS reagent, 37%
Sigma-Aldrich
Acido cloridrico, ACS reagent, 37%
Sigma-Aldrich
Cloruro di idrogeno, 4.0 M in dioxane
Sigma-Aldrich
Acido cloridrico, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Acido cloridrico, 37 wt. % in H2O, 99.999% trace metals basis
Sigma-Aldrich
Acido cloridrico, 36.5-38.0%, BioReagent, for molecular biology
Sigma-Aldrich
Cloruro di idrogeno, 2.0 M in diethyl ether
Sigma-Aldrich
Anti-laminina, 0.5 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Ethylenediaminetetraacetic acid solution, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Supelco
Acido cloridrico, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
Ethylenediaminetetraacetic acid, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
Ethylenediaminetetraacetic acid, 99.995% trace metals basis
Sigma-Aldrich
Ethylenediaminetetraacetic acid disodium salt solution, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O
Sigma-Aldrich
Cloruro di idrogeno, 1.0 M in diethyl ether
Sigma-Aldrich
Acido cloridrico, ~6 M in H2O, for amino acid analysis
Sigma-Aldrich
Ethylenediaminetetraacetic acid, anhydrous, BioUltra, ≥99% (titration)
Sigma-Aldrich
Ethylenediaminetetraacetic acid, purified grade, ≥98.5%, powder
Sigma-Aldrich
Cloruro di idrogeno, 3 M in cyclopentyl methyl ether (CPME)
Sigma-Aldrich
Acido cloridrico, 32 wt. % in H2O, FCC
Sigma-Aldrich
Cloruro di idrogeno, 1.0 M in acetic acid
Supelco
Hydrogen chloride – methanol solution, ~1.25 m HCl (T), for GC derivatization, LiChropur
Supelco
Hydrogen chloride – ethanol solution, ~1.25 M HCl, for GC derivatization, LiChropur
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ≥98.0% (KT)
Supelco
Hydrogen chloride – 2-propanol solution, ~1.25 M HCl (T), for GC derivatization, LiChropur
Sigma-Aldrich
Ethylenediaminetetraacetic acid, BioUltra, ≥99.0% (KT)